Vidcast: https://www.instagram.com/p/DJ9sa5bOFBx/

The FDA has just approved a new nasal powder spray called Atzumi that delivers the drug dihydroergotamine, or DHE via a novel nasal spray technology developed by Satsuma Pharmaceuticals. It’s the first and only product to use SMART, which stands for. Simple MucoAdhesive Release Technology. The drug is delivered in a powder with a unique ability to adhere on tissue linings thereby enhancing absorption. The DHE causes cerebral blood vessels to contract, blocks pain transmission, and inhibits inflammatory neurotransmitters all leading to migraine resolution.

The Atzumi migraine nasal spray was tested in the 12 month safety and tolerability ASCEND study involving 344 participants. Those using the spray after acute onset of migraine were surveyed at 2, 4, and 24 hours following symptom onset to assess its short and longer-term effects. At 2 hours, 37% were pain-free, 54% denied bothersome symptoms, and two-thirds had headache relief. These stats increased to 86%, 91%, and 94% by 24 hours.

Atzumi is FDA-approved for migraine treatment rather than migraine prevention. These preliminary results suggest that this nasal spray may be a powerful tool that can quickly and effectively eradicate migraines. It will also prove to be a welcome alternative for migraine sufferers who cannot tolerate other oral or injection therapies.

https://pubmed.ncbi.nlm.nih.gov/39373843/

https://www.medscape.com/viewarticle/fda-okays-dihydroergotamine-nasal-spray-acute-migraine-2025a1000auy

#migraine #nasal #powder #mucoadhesive #atzumi